Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2

Front Immunol. 2024 Mar 20:15:1353353. doi: 10.3389/fimmu.2024.1353353. eCollection 2024.

Abstract

As severe acute respiratory coronavirus 2 (SARS-CoV-2) variants continue to emerge, it is important to characterize immune responses against variants which can inform on protection efficacies following booster vaccination. In this study, neutralizing breadth and antigen-specific CD8+ T cell responses were analyzed in both infection-naïve and infection-experienced individuals following administration of a booster bivalent Wuhan-Hu-1+BA.4/5 Comirnaty® mRNA vaccine. Significantly higher neutralizing titers were found after this vaccination compared to the pre-third booster vaccination time point. Further, neutralizing breadth to omicron variants, including BA.1, BA.2, BA.5, BQ.1 and XBB.1, was found to be boosted following bivalent vaccination. SARS-CoV-2-specific CD8+ T cells were identified, but with no evidence that frequencies were increased following booster vaccinations. Spike protein-specific CD8+ T cells were the only responses detected after vaccination and non-spike-specific CD8+ T cells were only detected after infection. Both spike-specific and non-spike-specific CD8+ T cells were found at much lower frequencies than CD8+ T cells specific to cytomegalovirus (CMV), Epstein-Barr virus (EBV) and influenza (Flu). Taken together, these results show that the bivalent Wuhan-Hu-1+BA.4/5 Comirnaty® mRNA vaccine boosted the breadth of neutralization to newer SARS-CoV-2 variants and that vaccination is able to induce spike protein-specific CD8+ T cell responses, which are maintained longitudinally.

Keywords: CD8 T cells; COVID-19; SARS-CoV-2; neutralization; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Neutralizing
  • BNT162 Vaccine
  • CD8-Positive T-Lymphocytes
  • COVID-19* / prevention & control
  • Epstein-Barr Virus Infections*
  • Herpesvirus 4, Human
  • Humans
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • mRNA Vaccines

Substances

  • Antibodies, Neutralizing
  • BNT162 Vaccine
  • Spike Glycoprotein, Coronavirus
  • mRNA Vaccines
  • spike protein, SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from The Capital Region of Denmark’s Research Foundation (CS, JB), the Novo Nordisk Foundation (AU, NW, JB), the Independent Research Fund Denmark (JB), the Candys Foundation (JB), Mauritzen La Fontaine Familiefond (JB), and the Danish Agency for Science and Higher Education (SR, JB).